Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.320
-0.130 (-3.77%)
At close: Feb 21, 2025, 4:00 PM
3.360
+0.040 (1.20%)
After-hours: Feb 21, 2025, 4:22 PM EST
Agenus Revenue
Agenus had revenue of $25.11M in the quarter ending September 30, 2024, with 3.28% growth. This brings the company's revenue in the last twelve months to $160.43M, up 59.00% year-over-year. In the year 2023, Agenus had annual revenue of $156.31M with 59.47% growth.
Revenue (ttm)
$160.43M
Revenue Growth
+59.00%
P/S Ratio
0.43
Revenue / Employee
$412,409
Employees
389
Market Cap
77.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AGEN News
- 9 days ago - Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting - Business Wire
- 23 days ago - Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas - Business Wire
- 4 weeks ago - Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease - Business Wire
- 2 months ago - Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers - Business Wire
- 2 months ago - Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs - Business Wire
- 3 months ago - Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment - Business Wire
- 3 months ago - Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development - Business Wire